Literature DB >> 26369956

In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii.

J Córdoba1, N M Coronado-Álvarez1, D Parra1, J Parra-Ruiz2.   

Abstract

Extensively drug-resistant (XDR) Acinetobacter spp. have emerged as a cause of nosocomial infections, especially under conditions of intensive care. Unfortunately, resistance to colistin is increasing and there is a need for new therapeutic options. We aimed to study the effect of some novel combinations against XDR Acinetobacter baumannii in an in vitro pharmacokinetics-pharmacodynamics (PK/PD) model. Three nonrelated clinical strains of XDR A. baumannii were investigated. Antibiotic-simulated regimens were colistin at 3 MU every 8 h (q8h) (first dose, 6 MU), daptomycin at 10 mg/kg of body weight q24h, imipenem at 1 g q8h, and ertapenem at 1 g q24h. Combination regimens included colistin plus daptomycin, colistin plus imipenem, and imipenem plus ertapenem. Samples were obtained at 0, 1, 2, 4, 8, and 24 h. Among the single-agent regimens, only the colistin regimen resulted in significant reductions in log10 CFU per milliliter compared to the control for all the strains tested. Although colistin achieved bactericidal activity at 4 h, it was not able to reach the limit of detection (1 log10 CFU/ml). One strain had significant regrowth at 24 h without the emergence of resistance. Daptomycin-colistin combinations led to a significant reduction in levels of log10 CFU per milliliter that were better than those achieved with colistin as a single-agent regimen, reaching the limit of detection at 24 h against all the strains. The combination of imipenem plus ertapenem outperformed the colistin regimen, although the results did not reach the limit of detection, with significant regrowth at 24 h. Similarly, colistin-plus-imipenem combinations reduced the levels of log10 CFU per milliliter at 8 h, with significant regrowth at 24 h but with development of resistance to colistin. We have shown some potentially useful alternatives for the treatment of extensively drug-resistant A. baumannii. Among them, the daptomycin-colistin combination was the most effective and should be investigated in future studies.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26369956      PMCID: PMC4649143          DOI: 10.1128/AAC.00493-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Pharmacokinetics of four different brands of colistimethate and formed colistin in rats.

Authors:  Hui He; Ji-Chang Li; Roger L Nation; Jovan Jacob; Gong Chen; Hee Ji Lee; Brian T Tsuji; Philip E Thompson; Kade Roberts; Tony Velkov; Jian Li
Journal:  J Antimicrob Chemother       Date:  2013-06-07       Impact factor: 5.790

2.  Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis.

Authors:  Ravina Kullar; Ian McClellan; Matthew Geriak; George Sakoulas
Journal:  Pharmacotherapy       Date:  2014-03-21       Impact factor: 4.705

Review 3.  Carbapenems.

Authors:  Dominique Breilh; Jeannette Texier-Maugein; Bernard Allaouchiche; Marie-Claude Saux; Emmanuel Boselli
Journal:  J Chemother       Date:  2013-02       Impact factor: 1.714

4.  Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii.

Authors:  Irene Galani; Konstantina Orlandou; Helen Moraitou; George Petrikkos; Maria Souli
Journal:  Int J Antimicrob Agents       Date:  2014-02-04       Impact factor: 5.283

5.  Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections.

Authors:  Alessandra Oliva; Alessandra D'Abramo; Claudia D'Agostino; Marco Iannetta; Maria T Mascellino; Carmela Gallinelli; Claudio M Mastroianni; Vincenzo Vullo
Journal:  J Antimicrob Chemother       Date:  2014-02-11       Impact factor: 5.790

6.  In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection.

Authors:  Michael Hornsey; Lynette Phee; Christopher Longshaw; David W Wareham
Journal:  Int J Antimicrob Agents       Date:  2013-01-09       Impact factor: 5.283

Review 7.  Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.

Authors:  Arnold S Bayer; Tanja Schneider; Hans-Georg Sahl
Journal:  Ann N Y Acad Sci       Date:  2012-12-05       Impact factor: 5.691

8.  In vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens.

Authors:  L Phee; M Hornsey; D W Wareham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-23       Impact factor: 3.267

9.  Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity.

Authors:  N Thibault; L Grenier; M Simard; M G Bergeron; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

10.  Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria.

Authors:  Nicola Petrosillo; Maddalena Giannella; Massimo Antonelli; Mario Antonini; Bruno Barsic; Laura Belancic; Cagkan Inkaya A; Gennaro De Pascale; Elisabetta Grilli; Mario Tumbarello; Murat Akova
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

View more
  5 in total

Review 1.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

Review 2.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 3.  Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options.

Authors:  Chang-Ro Lee; Jung Hun Lee; Moonhee Park; Kwang Seung Park; Il Kwon Bae; Young Bae Kim; Chang-Jun Cha; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Cell Infect Microbiol       Date:  2017-03-13       Impact factor: 5.293

4.  Quercetin Rejuvenates Sensitization of Colistin-Resistant Escherichia coli and Klebsiella Pneumoniae Clinical Isolates to Colistin.

Authors:  Yishuai Lin; Ying Zhang; Shixing Liu; Dandan Ye; Liqiong Chen; Na Huang; Weiliang Zeng; Wenli Liao; Yizhou Zhan; Tieli Zhou; Jianming Cao
Journal:  Front Chem       Date:  2021-11-25       Impact factor: 5.221

5.  Thymol Increases Sensitivity of Clinical Col-R Gram-Negative Bacteria to Colistin.

Authors:  Zhuocheng Yao; Luozhu Feng; Yining Zhao; Xiaodong Zhang; Lijiang Chen; Lingbo Wang; Ying Zhang; Yao Sun; Tieli Zhou; Jianming Cao
Journal:  Microbiol Spectr       Date:  2022-06-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.